Document:

Exhibit 10.2

		

			Exhibit 10.2

		

		

			CONFIDENTIAL TREATMENT REQUEST – EDITED COPY

		

		

			 

		

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		
			AMENDMENT NO. 1
TO
MANUFACTURING SERVICES AGREEMENT
		

		
			THIS AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No. 1”) is made as of March 22, 2015, by and between SciClone Pharmaceuticals International Ltd. (“Customer”); and Lonza Sales Ltd (“Lonza”).
		

		
			WITNESSETH:
		

		
			WHEREAS, Customer and Lonza are party to that certain Manufacturing Services Agreement, dated as of April 30, 2014, (the “Agreement”); and
		

		
			WHEREAS, the parties wish to amend the Agreement as more fully set forth herein;
		

		
			NOW, THEREFORE, for and in consideration of the premises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
		

			
	
			
				 1.
			Capitalized terms used in this Amendment No. 1 and not otherwise defined herein shall have the respective meanings set forth in the Agreement.

			
	
			
				 2.
			The Agreement is hereby amended to add Appendix A attached hereto as Project Plan SL-001 under the Agreement, effective as of the date first above written.  Project Plan SL-001 supersedes any previous Project Plan under the Agreement relating to the services described in Project Plan SL-001.

			
	
			
				 3.
			The Agreement is hereby amended to add Appendix C attached hereto, effective as of the date first above written.  The attached Appendix C supersedes any previous version of Appendix C.

			
	
			
				 4.
			Except as expressly set forth in this Amendment No. 1, the terms and conditions of the Agreement shall remain in full force and effect.

		
			IN WITNESS WHEREOF, each of the parties hereto has executed, or has caused its duly authorized officer to execute, this Amendment No. 1 as of the date first above written.
		

			
					
						﻿

					
					
						 

				
	
					
						SciClone Pharmaceuticals International Ltd.

					
					
						Lonza Sales Ltd

				
	
					
						By: /s/ Friedhelm Blobel

					
					
						By: /s/ Marie Leblanc

				
	
					
						Name: Friedhelm Blobel

					
					
						Name: Marie Leblanc

				
	
					
						Title: Director

					
					
						Title: Associate Director Key Account Management

				
	
					
						﻿

					
					
						By: /s/ Nadia Ziegler

				
	
					
						﻿

					
					
						Name: Nadia Ziegler

				
	
					
						﻿

					
					
						Title: Senior Legal Counsel

				

		

		

		 

 

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		Appendix A
		

		
			PROJECT PLAN SL-001
		

		
			﻿
		

		
			[***] 
		

		
			﻿
		

		
			 
		

		

		

		 

 

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		Appendix C
		

		
			SPECIFICATIONS
		

		
			﻿
		

		
			[***] 
		

		
			﻿Exhibit 10.3

		

			Exhibit 10.3

		

		

			CONFIDENTIAL TREATMENT REQUEST – EDITED COPY

		

			

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			AMENDMENT NO. 2
		

		
			TO
		

		
			the Manufacturing Services Agreement
(the “Agreement”)
		

		
			effective April 30, 2014
		

		
			between
		

		
			Lonza Sales Ltd
		

		
			and
		

		
			SciClone Pharmaceuticals International Ltd
		

		
			 
		

		

		

		 

 

		

			 

		

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		THIS AMENDMENT is made the 22nd of, July 2015 (the "Amendment Effective Date")
		

		
			BETWEEN
		

		
			Lonza Sales Ltd, of Munchensteinerstrasse 38, CH-4002 Basel, Switzerland (“Lonza"),
		

		
			and
		

		
			SciClone Pharmaceuticals International Ltd., Ugland House, South Church Street George Town, Grand Cayman, Cayman Islands, USA (“Customer”)
		

		
			WHEREAS
		

			
	
			
				 A.
			

			
	
			
			Customer and Lonza are parties to an agreement effective April 30, 2014 as amended (the "Agreement"), under which Lonza is required to perform Services, and

			
	
			
				 B.
			

			
	
			
			Customer would like Lonza to carry out additional activities under the Agreement, and

			
	
			
				 C.
			

			
	
			
			Lonza is prepared to perform the additional activities; and

			
	
			
				 D.
			

			
	
			
			the Parties are desirous of further amending the Agreement to reflect the agreed upon changes in the Services and the pricing therefore.

		
			﻿
		

		
			NOW THEREFORE in consideration of the above premises and the mutual covenants herein it is agreed hereby by the parties to amend the Agreement to include performance of the additional Services and the pricing therefore as follows:
		

		
			Capitalized terms used but not otherwise defined herein shall have the meanings afforded to them in the Agreement.
		

		

		

		 

		

			2

		

		

			 

		

 

		

			 

		

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		
		

		
			﻿
		

			
	
			
				 1.
			

			
	
			
			The Agreement shall be amended to include the additional Services contained in in Exhibit A and the parties agree that Lonza shall perform these detailed activities at the direction of the Customer.

			
	
			
				 2.
			

			
	
			
			Remainder of Agreement. Except as modified by this Amendment all other terms and conditions of the Agreement as previously amended shall remain in full force and effect.

			
	
			
				 3.
			

			
	
			
			Entire Agreement. This Amendment and the Agreement supersede all other prior agreements, understandings, representations and warranties, oral or written between the parties hereto in respect of the subject matter hereof.

		
			IN WITNESS WHEREOF the parties have caused this Amendment No. 18 to be executed by their representatives thereunto duly authorised as of the dates below, effective as of the Effective Date.
		

			
					
						﻿

					
					
						 

				
	
					
						Signed for and on behalf of

					
					
						/s/ Fabrice Gachot; /s/ Nadia Zieger

				
	
					
						LONZA SALES LTD

					
					
						TITLE: Director; Senior Legal Counsel

				
	
					
						﻿

					
					
						DATE: 22 July 2015

				
	
					
						﻿

					
					
						 

				

		
			﻿
		

			
					
						﻿

					
					
						 

				
	
					
						Signed for and on behalf of

					
					
						 /s/ Friedhelm Blobel

				
	
					
						SCICLONE PHARMACEUTICALS
INTERNATIONAL LTD

					
					
						TITLE: Director

				
	
					
						﻿

					
					
						DATE: July 17, 2015 

				

			
					
						﻿

					
					
						 

				
	
					
						﻿

					
					
						 

				
	
					
						﻿

					
					
						 

				

		
			﻿
		

		

		

		 

		

			3

		

		

			 

		

 

		

			 

		

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		
		

		
			﻿
		

		
			Exhibit A:
		

		
			﻿
		

		
			[***] 
		

		
			﻿
		

		
			﻿
		

		 

		

			4Exhibit 10.4

		

			Exhibit 10.4

		

		

			CONFIDENTIAL TREATMENT REQUEST – EDITED COPY

		

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		
			AMENDMENT NO. 3
TO
MANUFACTURING SERVICES AGREEMENT
		

		
			THIS AMENDMENT NO. 3 TO MANUFACTURING SERVICES AGREEMENT (this “Amendment No. 3”) is made as of December 9th, 2015, by and between SciClone Pharmaceuticals International Ltd. (“Customer”); and Lonza Sales Ltd (“Lonza”).
		

		
			WITNESSETH:
		

		
			WHEREAS, Customer and Lonza are party to that certain Manufacturing Services Agreement, dated as of April 13, 2014, (the “Agreement”).
		

		
			WHEREAS, the parties wish to amend the Agreement as more fully set forth herein;
		

		
			NOW, THEREFORE, for and in consideration of the premises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
		

			
	
			
				 1.
			Capitalized terms used in this Amendment No. 3 and not otherwise defined herein shall have the respective meanings set forth in the Agreement.

			
	
			
				 2.
			The Agreement is hereby amended to add Appendix C attached hereto, effective as of the date first above written.  The attached Appendix C supersedes any previous version of Appendix C.

			
	
			
				 3.
			Except as expressly set forth in this Amendment No. 3, the terms and conditions of the Agreement shall remain in full force and effect.

		
			IN WITNESS WHEREOF, each of the parties hereto has executed, or has caused its duly authorized officer to execute, this Amendment No. 3 as of the date first above written.
		

			
					
						﻿

					
					
						 

					
					
						 

				
	
					
						﻿

					
					
						 

					
					
						 

				
	
					
						SciClone Pharmaceuticals International Ltd.

					
					
						Lonza Sales Ltd.

				
	
					
						﻿

					
					
						 

				
	
					
						By: /s/ Friedhelm Blobel

					
					
						By: /s/ Albert Pereda

				
	
					
						Name: Friedhelm Blobel

					
					
						Name: Albert Pereda

				
	
					
						Title: Director

					
					
						Title: Legal Counsel

				
	
					
						﻿

					
					
						 

				
	
					
						﻿

					
					
						By: /s/ Michael Maskus

				
	
					
						﻿

					
					
						Name: Michael Maskus

				
	
					
						﻿

					
					
						Title: Associate Director Commercial

				
	
					
						﻿

					
					
						Development

				

		
			﻿
		

		
			 
		

		

		

		 

 

			

					

						 

				
	

					

						*** CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS EXHIBIT.  CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE DESIGNATED BY [***].  A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

				

		

			 

		

		EXHIBIT C
		

		
			SPECIFICATIONS
		

		
			﻿
		

		
			[***] 
		

		
			﻿
		

		
			﻿

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]